AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Healthcare
Mayne Pharma Shareholders Endorse $672M Cosette Deal as ASX200 Court Clash Looms
June 18, 2025 01:12 PM AEST| By Team Kalkine MediaHighlights,Mayne Pharma investors overwhelmingly support $672M Cosette acquisition,Legal battle over deal termination to unfold in September,Mayne Pharma’s stock trades below the agreed acquisition value,Mayne Pharma Group Ltd (ASX:MYX), a pharmaceut...
Neuren Pharmaceuticals Sees ASX200 Momentum as Market Eyes EMA Approval
June 18, 2025 01:09 PM AEST| By Team Kalkine MediaHighlights,Neuren,Pharmaceuticals shares gain amid strategic momentum,Royalty-rich partnership with Acadia drives earnings leverage,EMA approval eyed, boosting potential future revenue,Neuren Pharmaceuticals (ASX:NEU), a biopharmaceutical company kno...
Cochlear’s New Tech Sparks Market Enthusiasm as ASX200 Giant Targets Global Growth
June 18, 2025 10:46 AM AEST| By Team Kalkine MediaHighlights,Cochlear expects growth with new product release,Nucleus,Nexa,may strengthen global market share,Services revenue projected to rise 40% in three years,Cochlear Limited (ASX:COH), a prominent player in the global hearing solutions industry...
Pro Medicus (ASX:PME) Strengthens Position in Radiology Software Sector | ASX 200
June 17, 2025 07:51 PM AEST| By Team Kalkine MediaHighlights,Pro Medicus Ltd (ASX:PME) delivers healthcare imaging software across global markets,The company forms part of the ASX 200, contributing to the broader australian share market,Strong focus on innovation with a history of software developme...
4DMedical (ASX:4DX) Expands Stanford Partnership, Strengthening ASX300 Medical Imaging Innovation
June 17, 2025 03:24 PM AEST| By Team Kalkine MediaHighlights,4DMedical (4DX) renews and expands contract with Stanford’s 3DQ Lab,Agreement includes cutting-edge lung imaging tech ahead of FDA clearance,Enhanced U.S. research foothold supports momentum within ASX300 stocks,4DMedical Limited (ASX:4DX)...
Recce Pharmaceuticals (ASX:RCE) Strengthens Clinical Pipeline via Avenue Capital Deal | ASX 200
June 17, 2025 03:01 PM AEST| By Team Kalkine MediaHighlights,Recce Pharmaceuticals secures a significant non-dilutive facility from Avenue Capital to enhance its late-stage clinical trials.,Funding supports registrational Phase 3 trials of R327G in Australia and Indonesia.,Pro-forma cash position en...
CSL (ASX:CSL) Advances in ASX300 with FDA Nod for Innovative HAE Therapy
June 17, 2025 02:30 PM AEST| By Team Kalkine MediaHighlights,CSL (CSL) gains FDA approval for new HAE treatment.,ANDEMBRY becomes first XIIa-targeting therapy for HAE prevention.,Immediate US launch expected through specialty pharmacy network.,CSL Limited (ASX:CSL), one of the prominent,ASX300 stock...
Clarity Pharmaceuticals (ASX:CU6) Secures Manufacturing Deal to Accelerate Commercial Launch
June 17, 2025 12:01 PM AEST| By Team Kalkine MediaHighlights,Clarity Pharmaceuticals signs major U.S. manufacturing deal,Production capacity set to reach 400,000 doses annually,Deal paves way for commercial launch post FDA nod,Clarity Pharmaceuticals (ASX:CU6), a clinical-stage radiopharmaceutical c...
Biotech Player CSL Gains FDA Nod for Rare Genetic Disorder Therapy
June 17, 2025 10:50 AM AEST| By Team Kalkine MediaHighlights,CSL (CSL) secures FDA approval for new HAE treatment,Andembry,to launch in the US for patients aged 12 and above,CSL strengthens its global leadership in rare disease therapies,Global biotechnology leader CSL (ASX:CSL), part of the ASX200...
CSL (ASX:CSL) Strengthens Its Footing in S&P/ASX 200 Healthcare Space
June 16, 2025 05:21 PM AEST| By Team Kalkine MediaHighlights,CSL Limited (ASX:CSL) operates in global biotechnology and is part of the S&P/ASX 200 index.,The company’s three core divisions—CSL Behring, CSL Seqirus, and CSL Vifor—serve key areas of healthcare worldwide.,CSL maintains a reputation for...
Breakthrough Response Observed in Amplia's Pancreatic Cancer Trial
June 16, 2025 12:56 PM AEST| By Team Kalkine MediaHighlights,Amplia Therapeutics reports rare complete response in metastatic pancreatic cancer trial,Narmafotinib shows potential in combination with standard chemotherapy,Fast-track status granted by FDA supports accelerated development,Amplia Therap...
Regulatory Scrutiny Deepens: Monash IVF Faces Pressure Amid Embryo Mix-Up Fallout
June 16, 2025 12:40 PM AEST| By Team Kalkine MediaHighlights,Shares of Monash IVF drop further after regulatory scrutiny,ASX seeks clarity on timing of disclosure,Ongoing concerns,emerge,over embryo transfer protocols,Monash IVF (ASX:MVF) is once again under market pressure as its shares fell sharpl...
EVE Health to Launch Digital Prescription Access for ED and Period Pain Products
June 16, 2025 11:50 AM AEST| By Team Kalkine MediaHighlights,EVE Health and,TeleDocs,partner for digital treatment access,New oral therapies for ED and period pain near launch,Strategic acquisition positions EVE in pharmaceutical market,EVE Health Group’s (ASX:EVE) expansion into regulated pharmaceu...
Courtroom Showdown Looms Over $672M Mayne Pharma Deal as Cosette Seeks Termination
June 16, 2025 11:02 AM AEST| By Team Kalkine MediaHighlights,Court hearing scheduled for 9 September over acquisition dispute,Cosette alleges breaches and seeks breakup fee or damages,Shareholder,vote on takeover set for 18 June,A high-stakes legal showdown is taking shape in the pharmaceutical sect...
Cochlear (ASX:COH) Faces Market Shifts Amid Healthcare Sector Moves
June 13, 2025 07:20 PM AEST| By Team Kalkine MediaHighlights,Cochlear (ASX:COH) updates FY25 within ASX 100 and ASX 200,Healthcare sector movements reflect varied product and service performance,New cochlear implant system launched amid broader market developments,Cochlear Limited (ASX:COH), listed...
Kalkine: Syntara Moves Closer to Breakthrough with Encouraging Myelofibrosis Trial Progress
June 13, 2025 03:59 PM AEST| By Team Kalkine MediaHighlights,Syntara receives fast track status for SNT-5505,Promising results continue in myelofibrosis Phase 2 trial,Final results and pivotal study discussions expected in 2025,Clinical-stage biopharmaceutical company Syntara (ASX:SNT) has reported...
Kalkine: Clarity Pharmaceuticals Surges on Encouraging Prostate Cancer Diagnostic Trial Outcomes
June 13, 2025 12:23 PM AEST| By Team Kalkine MediaHighlights,Shares rose after positive trial update,Cu-SAR-Bombesin shows high diagnostic efficacy,Next steps include registration and broader oncology focus,Clarity Pharmaceuticals (ASX:CU6) experienced a notable market response following the release...
Kalkine: HITIQ (ASX:HIQ) Signs Game-Changing Global Deal with Shock Doctor to Advance Athlete Safety
June 12, 2025 06:27 PM AEST| By Team Kalkine MediaHighlights,HITIQ teams up globally with Shock Doctor,Innovative concussion tech in self-fit mouthguards,New product rollout begins with sports partners in 2025,HITIQ (ASX:HIQ), an innovator in sports technology, has taken a significant leap forward i...
Kalkine: AnteoTech (ASX:ADO) Accelerates Growth with Surge in Life Sciences Revenue and Strategic Global Progress
June 12, 2025 06:09 PM AEST| By Team Kalkine MediaHighlights,AnteoTech (ADO) expects 130% growth in Life Sciences sales for FY2025,Serum Institute places major order for AnteoBind™ valued at A$213,000,Key R&D milestones achieved despite delays in some global projects,AnteoTech (ASX:ADO), a leading n...
Kalkine: EVE Health Group (ASX:EVE) Strengthens Position in Regulated Healthcare with Nextract Acquisition
June 12, 2025 06:06 PM AEST| By Team Kalkine MediaHighlights,EVE completes strategic acquisition of Nextract Pty Ltd,New therapeutic products target major global health markets,Leadership reshuffle supports growth in regulated healthcare,EVE Health Group (ASX:EVE) has officially finalized the acquis...
Advertise your brand on Kalkine Media